HRMY - Harmony Biosciences Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.00
DETAILS
HIGH:
$50.00
LOW:
$31.00
MEDIAN:
$45.50
CONSENSUS:
$43.00
UPSIDE:
42.62%
About Harmony Biosciences Holdings, Inc. (https://www.harmonybiosciences.com)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jeffrey Dayno | President, Chief Executive Officer & Director | 1957 | $1,324,015 USD |
| Sandip S. Kapadia | Executive Vice President, Chief Administrative Officer & Chief Financial Officer | 1970 | $1,064,327 USD |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer | 1973 | $946,228 USD |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer | 1971 | $919,062 USD |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer | 1975 | $681,398 USD |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman | 1968 | $77,500 USD |
| Peter Anastasiou | Chief Operating Officer | 1970 | $58,250 USD |
| Audrey Murphy | Chief Human Resources Officer | – | – |
| Brennan Doyle | Vice President & Head of Investor Relations | – | – |
| Cate McCanless | Senior Vice President & Chief Corporate Affairs Officer | – | – |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary | – | – |
| Glenn Reicin | Chief Financial Officer | 1965 | – |
| Tricia Glover | Chief Compliance Officer | – | – |